New acute onset of ocular myasthenia gravis after COVID-19 vaccine: A case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 37090999.
- Also identified by DOI 10.4103/jfmpc.jfmpc_1359_22 and PMC identifier 10114583.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Reports have shown the association of coronavirus disease 2019 (COVID-19) with several neuromuscular disorders. Myasthenia gravis (MG) is an autoimmune disease in which antibodies bind to acetyl choline receptors in the postsynaptic membrane at the neuromuscular junction. The characteristic clinical feature of the disease is weakness of the ocular muscle, bulbar muscle, and extremity muscles; when the weakness is limited to the ocular muscle only, the condition is known as ocular myasthenia gravis. Diagnosis is usually confirmed by the acetylcholine receptor antibodies. Symptoms of MG may be aggravated by various types of infections and medications. Here, we are presenting a rare case of a new and acute onset of ocular MG presented after administration of Covishield vaccine.